Vergent Bioscience Secures $21.5 Million Series B Financing To Advance Clinical Development Of Tumor-Targeted Fluorescent Imaging Agent Vgt-309
Vergent Bioscience Secures $21.5 Million Series B Financing To Advance Clinical Development Of Tumor-Targeted Fluorescent Imaging Agent Vgt-309
10/04/22, 12:05 PM
Location
minneapolisMoney raised
$21.5 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, today announced the close of a $21.5 million Series B financing. Vergent will use the funds to advance clinical development of VGT-309, the company’s targeted fluorescent imaging agent that enables surgeons to see previously undetected or difficult-to-find tumors in real-time, ensuring all tumor tissue is removed during open, minimally invasive (MIS) and robotic-assisted surgical procedures.
Company Info
Location
minneapolis, minnesota, united states
Additional Info
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.
Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.
Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.